3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow ERYtech Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Eryaspase, FOLFIRINOX - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | Georgetown University | 19 | 2020-12-02 | 2025-06-11 |
| Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer GRASPA - Pancreatic Cancer | Phase 1 | Completed | ERYtech Pharma | 12 | 2009-11-01 | 2021-10-15 |
| Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia GRASPA, native L asparaginase - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | ERYtech Pharma | 25 | 2006-01-01 | 2012-01-11 |
Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · eryaspase (1) · folfirinox (1)
France (1) · United States (1)
Marcus S Noel, MD (1) · Yves Bertrand, MD PhD (1)